<DOC>
	<DOCNO>NCT00550771</DOCNO>
	<brief_summary>The purpose study compare incidence cardiac dysfunction subject human epidermal growth factor receptor 2 ( HER2 ) positive breast cancer treat either doxorubicin pegylated liposomal doxorubicin ( PLD ) , combination trastuzumab .</brief_summary>
	<brief_title>Phase II Trial Compare Safety Two Chemotherapy Plus Trastuzumab Regimens Adjuvant Therapy HER2-positive Breast Cancer ( Study P05048 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Subjects operable , nodepositive highrisk nodenegative ( see # 3 ) HER2positive breast carcinoma eligible study , provide satisfy follow criterion . Subjects must demonstrate willingness able participate study adhere dose visit schedule Subjects must female gender &gt; = 18 year age Subjects must diagnose operable , histologically confirm adenocarcinoma breast clinical radiological evidence metastatic disease otherwise high intermediate risk tumor characteristic : nodepositive : T13 , N12 , M0 ( level T [ tumor involvement ] , N [ lymph node involvement ] , &amp; M [ matastases ] ) OR nodenegative AND least one follow feature : Tumor &gt; 2 cm Tumor &gt; 1 cm Negative estrogen receptor/progesterone receptor ( ER/PR ) Malignancy Grade 23 Presence peritumoral vascular invasion Age &lt; 35 year HER2positive fluorescence situ hybridization ( FISH ) ( gene amplification ) 3+ use immunohistochemistry Subjects must complete resection ( R0 ) primary tumor axillary lymph node ( must negative sentinel node [ ] ) Baseline leave ventricular ejection fraction ( LVEF ) multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) &gt; =55 % Easter Cooperative Oncology Group ( ECOG ) performance status 01 Adequate postoperative bone marrow function neutrophil &gt; =1.5 x 10^9/l , platelet &gt; =100 x 10^9/l hemoglobin &gt; = low limit normal ( LLN ) Adequate renal function : calculated creatinine clearance &gt; =50 ml/min Adequate postoperative liver function total bilirubin &lt; upper limit normal ( ULN ) , alkaline phosphatase &lt; 2.5 time ULN aspartate aminotransferase ( AST ) &lt; 1.5 time ULN Subjects must free clinically relevant disease would , principal investigator 's and/or sponsor 's opinion , interfere conduct study study evaluation Subjects childbearing potential ( include woman less one year postmenopausal sexually active study ) must agree use medically accept method contraception , receive protocolspecified medication 30 day ( per local requirement ) stop medication surgically sterilize prior screen Subjects must able provide write informed consent Subject meet follow exclusion criterion disqualify participation study : Clinical radiological evidence metastatic disease Prior radiotherapy , chemotherapy biotherapy currently diagnose breast cancer prior randomization Clinically significant pericardial effusion Serious cardiac illness include , confine history document congestive heart failure history form cardiomyopathy active treatment form cardiomyopathy history angina pectoris document transmural myocardial infarction , active angina pectoris require medication serious ventricular arrhythmia require medication implantable cardioverterdefibrillator ( ICD ) therapy , uncontrolled supraventricular arrhythmia clinically significant valvular disease poorly control arterial hypertension ( systolic blood pressure ( BP ) &gt; 180 mmHg , diastolic BP &gt; 100 mmHg ) Sensory/motor neuropathy &gt; grade 2 defined National Cancer Institure Common Toxicity Criteria ( NCICTC ) Pregnancy , intend become pregnant study Nursing ( breastfeed ) intend nurse study Any follow clinical condition : Chronic obstructive pulmonary disease , require chronic treatment Clinically significant active infection A history psychological illness condition , prevent subject understand requirement study Unstable regulation diabetes mellitus A situation condition , opinion investigator , may interfere optimal participation study Is staff , affiliate , family member staff personnel directly involve study Usage investigational product within 30 day prior enrollment Participation interventional clinical study involve drug , device biological . This would prohibit patient participate quality life ( QOL ) , questionnaire , blood collection , observational study . Allergy sensitivity study drug excipients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>